Clinical trials: AIDS Vaccines
HIV-1 Infection, HIV Infections
A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
The purpose of the study is to find out whether an experimental autologous dendritic cell vaccine is safe, well tolerated, and whether it can strengthen the immune system's response to HIV.
- Trial name
- PARC002 (NCT00833781)
- Testing
- mRNA-transfected autologous dendritic cells, autologous dendritic cells with no mRNA transfection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Polio Immunity
Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects
The purpose of this study is to determine whether a lower dose of inactivated polio vaccine (IPV) injected into the skin (intradermal administration) can work equally well or better than the standard dose injected into the muscle…
- Trial name
- IDIPV (NCT01686503)
- Testing
- IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- Eastern Virginia Medical School
HIV Infection
Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers
The development of a safe and effective HIV-1 vaccine strategy would probably be the best solution for the ultimate control of the worldwide AIDS pandemic.
- Trial name
- VRI01 (NCT02038842)
- Testing
- LIPO-5, MVA HIV-B (MVATG17401), GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Herpes Zoster
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
This observer-blind study will evaluate the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational Herpes Zoster (HZ) vaccine GSK1437173A in Human Immunodeficiency Virus (HIV) infected subjects, firstly…
- Trial name
- NCT01165203
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 15 sites in United States, Germany and 1 more
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
HIV-1, HIV Infections
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
The goal of this study is to understand the safety, tolerability and immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd 5 HIV-1 gag/pol/nef) vaccine in healthy human volunteers compared…
- Trial name
- NCT00849680
- Testing
- Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose), Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose), Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
- Volunteers
- 317 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV vaccine (gp145 C.6980) with aluminum hydroxide adjuvant in healthy, HIV-1-uninfected adults in the United States.
- Trial name
- NCT03382418
- Testing
- gp145 C.6980 Vaccine, Aluminum Hydroxide Adjuvant
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus, HIV Infections
Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)
The purpose of this study is to evaluate the long-term persistence of binding antibody responses against V1V2 and gp120 in subjects who were vaccinated with the envelope glycoprotein 120 (gp120)-negative factor (Nef)Tat/ Adjuvant…
- Trial name
- NCT03368053
- Testing
- Blood sampling
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infection
HIV Vaccine Trial in Thai Adults
The purpose of this study is to determine whether immunizations with an integrated combination of ALVAC-HIV (vCP1521) boosted by AIDSVAX gp120 B/E prevent HIV infection in healthy Thai volunteers.
- Trial name
- NCT00223080
- Testing
- ALVAC-HIV vCP1521 + AIDSVAX
- Where
- 8 sites in Thailand
- Volunteers
- 16,402 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
HIV Infections
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men.
- Trial name
- NCT00865566
- Testing
- DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine
- Where
- 22 sites in United States
- Volunteers
- 2,504 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines
The object of the study is to assess the safety profile of candidate vaccines ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVcnsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers.
- Trial name
- NCT04586673
- Testing
- ChAdOx1.tHIVconsv1 (C1), MVA.tHIVconsv3 (M3), MVA.tHIVconsv4 (M4)
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Oxford
AIDS, HIV Infections
Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)
This study will test the safety and efficacy of an investigational Human Immunodeficiency Virus (HIV) vaccine. Efficacy will be measured by either prevention of HIV infection or control of HIV viral load in subjects who become…
- Trial name
- NCT00095576
- Testing
- Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
This study will evaluate the preventive vaccine efficacy, safety, and tolerability of ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 in HIV-seronegative South African adults over 24 months and potentially up to 36 months…
- Trial name
- HVTN702 (NCT02968849)
- Testing
- ALVAC-HIV (vCP2438), Bivalent Subtype C gp120/MF59
- Where
- 14 sites in South Africa
- Volunteers
- 5,404 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention
The purpose of this study is to assess the safety and tolerability of various regimens containing adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV), Modified Vaccinia Ankara (MVA)-Mosaic, and/or HIV type…
- Trial name
- NCT02315703
- Testing
- Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose
- Where
- 12 sites in United States, Rwanda and 3 more
- Volunteers
- 393 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Tuberculosis, HIV Infections
Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)
This is a phase II, proof of concept, randomized, double-blind, placebo-controlled study to evaluate the protective efficacy against TB disease, safety, and immunogenicity of MVA85A/AERAS-485 in healthy, HIV-infected adults.
- Trial name
- NCT01151189
- Testing
- MVA85A/AERAS-485
- Where
- 2 sites in Senegal, South Africa
- Volunteers
- 650 people
- Sponsor
- Aeras
HIV Infections, Systemic Lupus Erythematosus
Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus
The purpose of this study is to evaluate the breadth and potency of HIV-1 neutralizing antibody (nAb) responses and examine the safety and tolerability of an HIV gp120 protein vaccine (AIDSVAX® B/E) in HIV-uninfected adults…
- Trial name
- NCT03618056
- Testing
- AIDSVAX® B/E
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Sexually Transmitted Diseases
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
Human papillomavirus (HPV) is the most common sexually transmitted disease in the world. HPV infection can cause genital warts and certain cervical problems, including cervical cancer.
- Trial name
- NCT00604175
- Testing
- Quadrivalent HPV vaccine
- Where
- 61 sites in United States, Brazil and 2 more
- Volunteers
- 319 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster, HIV Infections
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy
Herpes zoster, or shingles, is the result of a viral infection that causes a painful skin rash, usually in older people or people with suppressed immune systems like those infected with HIV.
- Trial name
- NCT00851786
- Testing
- ZOSTAVAX
- Where
- 43 sites in United States
- Volunteers
- 395 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
Men who have sex with men (MSM) have an increased risk of developing anal human papillomavirus (HPV) infections, which can be a risk factor for anal cancer. HIV-infected women are also at risk of anal cancer.
- Trial name
- NCT01461096
- Testing
- Quadrivalent HPV Vaccine
- Where
- 24 sites in United States, Brazil and 1 more
- Volunteers
- 575 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Hepatitis B
Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
Hepatitis B is a contagious virus that can damage a person's liver. It can be prevented by vaccination, but for many HIV-positive people, the vaccines do not help them achieve adequate protection against this virus.
- Trial name
- NCT00106964
- Testing
- Engerix-B 20 mcg, Engerix-B 40 mcg, Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg
- Where
- 11 sites in United States, Brazil and 1 more
- Volunteers
- 371 people
- Sponsor
- University of North Carolina, Chapel Hill
Sexual Transmission of Infection
Preparedness Study - HPV Vaccine
Moffitt Cancer Center is the Coordinating Center for this study. The purpose of this study is to develop and test the infrastructure to conduct a future Phase III vaccine efficacy trial to assess trial feasibility, and to assess…
- Trial name
- NCT01489527
- Testing
- Gardasil Vaccine
- Where
- 2 sites in United States, South Africa
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute